Centrum 7/6  banner

clobazam oral suspension

Aurobindo receives FDA approval for clobazam oral suspension, 2.5 mg/mL

Aurobindo receives FDA approval for clobazam oral suspension, 2.5 mg/mL

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application clobazam oral suspension, 2.5m/mL. Aurobindo Pharma’s clobazam oral suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ONFI Oral Suspension, of Lundbeck Pharmaceuticals. Clobazam oral suspension are indicated for the

PP_1170x120_10-25-21